---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020604"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T13:03:26.094348+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q4 net loss $38.3M; cash $719.9M; NVL-520 gets FDA BTD

## Summary
- Cash, cash equivalents and marketable securities $719.9M at Dec 31, 2023; operating runway into 2027.
- Q4 net loss $38.3M, full year 2023 net loss $126.2M; R&D expenses $35.6M Q4 and $113.2M full year.
- FDA granted Breakthrough Therapy Designation to NVL-520 for ROS1+ NSCLC after 2+ prior TKIs.
- Initiated Phase 2 of ALKOVE-1 trial for NVL-655 at 150 mg once daily with registrational intent.
- Expect to initiate Phase 1 for HER2 program in 2024; promoted Matthew Metivier to SVP HR.

## SEC filing metadata
- accession: 0000950170-24-020604
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/nuvl-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020604
- JSON: https://secwatch.observer/filing/0000950170-24-020604.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020604.txt

## Key facts
- Earnings Releases
  Nuvalent, Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..
  - Period: the quarter and year ended December 31, 2023
  - Net income: Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023.
  - Result: reported results
  source text: On February 27, 2024, Nuvalent, Inc. announced its financial results for the quarter and year ended December 31, 2024, and other corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm
- Earnings Releases
  Nuvalent, Inc. reported the fourth quarter of 2023 and the year ended December 31, 2023 results: net income Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023..
  - Period: the fourth quarter of 2023 and the year ended December 31, 2023
  - Net income: Net loss was $38.3 million for the fourth quarter of 2023 and $126.2 million for the year ended December 31, 2023.
  - Result: reported results
  source text: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000095017024020604/0000950170-24-020604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.